Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals, Inc. on February 8, 2011. The report details corporate governance actions taken by the Board of Directors regarding executive compensation effective for the 2011 calendar year.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments.
Material Changes
- CEO Bonus Target Increase: The Board amended the Cash Bonus Plan to increase the Chief Executive Officer's annual bonus target from 60% to 65% of annual base salary, effective January 1, 2011.
- CEO Base Salary Increase: The Board approved a base salary increase for Mr. Cozadd to $575,000 per year, effective March 1, 2011.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, market outlook, or specific risk factors. It notes that actual cash bonuses are discretionary and determined by the Compensation Committee based on corporate and individual performance objectives. The amended Bonus Plan will be filed as an exhibit to the Company's annual report on Form 10-K for the year ended December 31, 2010.
Investor Verification Checklist
- Verify the exact effective dates for the bonus target change (Jan 1, 2011) and salary increase (Mar 1, 2011).
- Review the full text of the amended Cash Bonus Plan in the upcoming Form 10-K filing.
- Confirm the total compensation package for the CEO including the new base salary of $575,000 and the 65% bonus target.